Dr Jamie   Fletcher
Conjoint Senior Lecturer

Dr Jamie Fletcher

Bachelor of Medical Science (Hons.), University of Sydney

PhD, University of Sydney

medicine-health
Sch Women's&Children's Health

Research outline

I am a translational researcher based at the Children’s Cancer Institute, where I lead a team of postdoctoral researchers and students focused on the childhood solid tumour neuroblastoma. Children with high-risk neuroblastoma frequently relapse with incurable, drug resistant disease, resulting in long-term survival rates below 50%. We seek to understand the biology of neuroblastoma and to improve patient survival rates through:

  • Identifying molecular mechanisms underlying drug resistance
  • Developing small molecule inhibitors targeting drug resistance mechanisms, with particular focus on multidrug resistance proteins
  • Developing improved pre-clinical testing models for high-risk neuroblastoma, including patient-derived xenograft (PDX) models and models of metastatic disease
  • Modelling personalised medicine strategies, including molecular profiling and ex vivo drug sensitivity screening

My team applies high-throughput drug screening, genomic analysis, mouse models, cell biology and tissue-culture based approaches to the study of drug resistance mechanisms, personalised medicine and new drug development in high-risk neuroblastoma. Our high-risk neuroblastoma research is published in leading journals, including JNCI, Cancer Res, Oncogene, Eur J Cancer, Nature Reviews Cancer and Science Translational Medicine.

Sample publications

Kamili A, Gifford AJ, Li N, Mayoh C, Chow SO, Failes TW, Eden GL, Cadiz R, Xie J, Lukeis RE, Norris MD, Haber M, McCowage GB, Arndt GM, Trahair TN, Fletcher JI (2020) Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy. British Journal of Cancer Jan 10, 2020. doi: 10.1038/s41416-019-0682-4.

Koach J, Holien JK, …24 authors…Fletcher JI, Perini G, Parker MW, Cheung BB, Marshall GM. Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface. Cancer Research 79(21):5652-5667.

Huynh T, Murray J, Flemming CL, Kamili A, Hofmann U, Cheung L, Roundhill EA, Yu DMT, Webber HT, Schwab M, Henderson MJ, Haber M, Norris MD, Fletcher JI. (2019) CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth. Biochemical Pharmacology 172:113770.

Gana CC, Hanssen KM, Yu DM, Flemming CL, Wheatley MS, Conseil G, Cole SPC, Norris MD, Haber M, Fletcher JI (2019) MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells. Biochemical Pharmacology 168:237-248.

Gamble LD…24 authors…Fletcher JI, Marshall GM, Ziegler DS, Hogarty MD, Burns MR, Perini G, Norris MD, Haber M (2019) Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma. Science Translational Medicine 11 (477), eaau1099.

Fletcher JI, Ziegler DS, Trahair TN, Marshall GM, Haber M, Norris MD. (2018) Too many targets, not enough patients: rethinking neuroblastoma clinical trials. Nature Reviews Cancer 18(6):389-400

Murray J, Valli E, Yu DMT, Truong AM, Gifford AJ, Eden GL, Gamble LD, Hanssen KM, Flemming CL, Tan A, Tivnan A, Allan S, Saletta F, Cheung L, Ruhle M, Schuetz JD, Henderson MJ, Byrne JA, Norris MD, Haber M, Fletcher JI (2017) Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumor growth and sensitizes to irinotecan in vivo European Journal of Cancer 83:132-141.

Jung M, Russell AJ, Liu B, George J, Liu PY, Liu T, DeFazio A, Bowtell DD, Oberthuer A, London WB, Fletcher JI, Haber M, Norris MD, Henderson MJ. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers (2017) Cancer Research 77(4):971-981

O'Brien R, Tran SL, Maritz MF, Liu B, Kong CF, Purgato S, Yang C, Murray J, Russell AJ, Flemming CL, von Jonquieres G, Pickett HA, London WB, Haber M, Gunaratne PH, Norris MD, Perini G, Fletcher JI, MacKenzie KL. (2016) MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin Cancer Research 76(12):3604-17.

Lau DT, Flemming CL, Gherardi S, Perini G, Oberthuer A, Fischer M, Juraeva D, Brors B, Xue C, Norris MD, Marshall GM, Haber M, *Fletcher JI, *Ashton LJ (2015) MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma. Oncotarget 6:15510-23.

Cheung L, Yu DM, Neiron Z, Failes TW, Arndt GM, Fletcher JI (2015) Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen. Biochemical Pharmacology 93:380-8.

Cheung L, Flemming CL, Watt F, Masada N, Yu DM, Huynh T, Conseil G, Tivnan A, Polinsky A, Gudkov AV, Munoz MA, Vishvanath A, Cooper DM, Henderson MJ, Cole SP, Fletcher JI, Haber M, Norris MD. (2014) High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4). Biochemical Pharmacology 91:97-108.

Fletcher JI, Gherardi S, Murray J, Burkhart CA, Russell A, Valli E, Smith J, Oberthuer A, Ashton LJ, London WB, Marshall GM, Norris MD, Perini G, Haber M (2012) N-Myc regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastoma. Cancer Research 72(4):845-853.

Fletcher JI, Haber M, Henderson MJ, Norris MD (2010) ABC transporters in cancer: more than just drug efflux pumps. Nature Reviews Cancer 10, 147-56.

Fletcher JI, Meusburger S, Hawkins CJ, Riglar DT, Lee EF, Fairlie WD, Huang DCS, Adams JM (2008) Apoptosis is triggered when pro-survival Bcl-2 proteins cannot restrain Bax. Proceeding of the National Academy of Sciences USA 105, 18081-18087.

Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, Ierino H, Lee EF, Fairlie WD, Bouillet P, Strasser A, Kluck RM, Adams JM, Huang DC (2007) Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315, 856-859.

Phone
9385 1579
Location
Children's Cancer Institute Lowy Cancer Research Centre, UNSW Australia PO Box 81 Randwick 2031 Australia http://ccia.org.au

Publications

  • Book Chapters | 2014
    Dr Jamie Fletcher
    Fletcher J; Roundhill E; Haber M; Norris M, 2014, 'Clinical relevance of multidrug-resistance-proteins (MRPs) for anticancer drug resistance and prognosis', in Efferth T; Bonavida B (ed.), Resistancce to Targeted Anti-Cancer Therapeutics, Springer Press., pp. 27 - 52
    Book Chapters | 2012
    Dr Jamie Fletcher
    Fletcher JI; Haber M; Henderson M; Norris MD, 2012, 'Targeting Multidrug Resistance in Neuroblastoma', in Hayat MA (ed.), Pediatric Cancer Volume 1 Diagnosis, Therapy and Prognosis: Neuroblastoma, edn. Pediatric Cancer-Diagnosis Therapy and Prognosis, Springer, New York, USA, pp. 115 - 123, http://dx.doi.org/10.1007/978-94-007-2418-1_11
  • Journal articles | 2021
    Dr Jamie Fletcher
    Schilstra CE; Sansom-Daly UM; Schaffer M; Fardell JE; Anazodo AC; McCowage G; Fletcher J; Marshall GM; Buchhorn-White J; Evtushenko M; Trahair TN; Ellis SJ, 2021, '"We Have All This Knowledge to Give, So Use Us as a Resource": Partnering with Adolescent and Young Adult Cancer Survivors to Determine Consumer-Led Research Priorities', JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY, http://dx.doi.org/10.1089/jayao.2021.0052
    Journal articles | 2021
    Dr Jamie Fletcher
    Xiao L; Somers K; Murray J; Pandher R; Karsa M; Ronca E; Bongers A; Terry R; Ehteda A; Gamble LD; Issaeva N; Leonova KI; O'Connor A; Mayoh C; Venkat P; Quek H; Brand J; Kusuma FK; Pettitt JA; Mosmann E; Kearns A; Eden G; Alfred S; Allan S; Zhai L; Kamili A; Gifford AJ; Carter DR; Henderson MJ; Fletcher JI; Marshall G; Johnstone RW; Cesare AJ; Ziegler DS; Gudkov AV; Gurova KV; Norris MD; Haber M, 2021, 'Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.', Clin Cancer Res, vol. 27, pp. 4338 - 4352, http://dx.doi.org/10.1158/1078-0432.CCR-20-2357
    Journal articles | 2021
    Dr Jamie Fletcher
    Chen J; Nelson C; Wong M; Tee AE; Liu PY; La T; Fletcher JI; Kamili A; Mayoh C; Bartenhagen C; Trahair TN; Xu N; Jayatilleke N; Wong M; Peng H; Atmadibrata B; Cheung BB; Lan Q; Bryan TM; Mestdagh P; Vandesompele J; Combaret V; Boeva V; Wang JY; Janoueix-Lerosey I; Cowley MJ; MacKenzie KL; Dolnikov A; Li J; Polly P; Marshall GM; Reddel RR; Norris MD; Haber M; Fischer M; Zhang XD; Pickett HA; Liu T, 2021, 'Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy', Clinical Cancer Research, vol. 27, pp. 1438 - 1451, http://dx.doi.org/10.1158/1078-0432.CCR-20-3044
    Journal articles | 2021
    Dr Jamie Fletcher
    Grohmann C; Walker F; Devlin M; Luo MX; Chüeh AC; Doherty J; Vaillant F; Ho GY; Wakefield MJ; Weeden CE; Kamili A; Murray J; Po’uha ST; Weinstock J; Kane SR; Faux MC; Broekhuizen E; Zheng Y; Shield-Artin K; Kershaw NJ; Tan CW; Witchard HM; Ebert G; Charman SA; Street I; Kavallaris M; Haber M; Fletcher JI; Asselin-Labat ML; Scott CL; Visvader JE; Lindeman GJ; Watson KG; Burgess AW; Lessene G, 2021, 'Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors', Cell Death and Disease, vol. 12, http://dx.doi.org/10.1038/s41419-020-03269-0
    Journal articles | 2020
    Dr Jamie Fletcher
    Huynh T; Murray J; Flemming CL; Kamili A; Hofmann U; Cheung L; Roundhill EA; Yu DMT; Webber HT; Schwab M; Henderson MJ; Haber M; Norris MD; Fletcher JI, 2020, 'CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth', Biochemical Pharmacology, vol. 172, http://dx.doi.org/10.1016/j.bcp.2019.113770
    Journal articles | 2020
    Dr Jamie Fletcher
    Khan A; Valli E; Lam H; Scott DA; Murray J; Hanssen KM; Eden G; Gamble LD; Pandher R; Flemming CL; Allan S; Osterman AL; Haber M; Norris MD; Fletcher JI; Yu DMT, 2020, 'Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition', Oncogene, vol. 39, pp. 3555 - 3570, http://dx.doi.org/10.1038/s41388-020-1235-2
    Journal articles | 2020
    Dr Jamie Fletcher
    Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T, 2020, 'Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma', International Journal of Cancer, vol. 147, pp. 1928 - 1938, http://dx.doi.org/10.1002/ijc.32936
    Journal articles | 2020
    Dr Jamie Fletcher
    Fordham AM; Xie J; Gifford AJ; Wadham C; Morgan LT; Mould EVA; Fadia M; Zhai L; Massudi H; Ali ZS; Marshall GM; Lukeis RE; Fletcher JI; MacKenzie KL; Trahair TN, 2020, 'CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma', British Journal of Cancer, vol. 123, pp. 1101 - 1113, http://dx.doi.org/10.1038/s41416-020-0996-2
    Journal articles | 2020
    Dr Jamie Fletcher
    Gao J; Jung MS; Mayoh C; Venkat P; Hannan KM; Fletcher JI; Kamili A; Gifford AJ; Kusnadi EP; Pearson RB; Hannan RD; Haber M; Norris MD; Somers K; Henderson MJ, 2020, 'Suppression of ABCE1-mediated mRNA translation limits N-MYC-driven cancer progression', Cancer Research, vol. 80, pp. 3706 - 3718, http://dx.doi.org/10.1158/0008-5472.CAN-19-3914
    Journal articles | 2020
    Dr Jamie Fletcher
    Le Grand M; Kimpton K; Gana CC; Valli E; Fletcher JI; Kavallaris M, 2020, 'Targeting Functional Activity of AKT Has Efficacy against Aggressive Neuroblastoma', ACS Pharmacology and Translational Science, vol. 3, pp. 148 - 160, http://dx.doi.org/10.1021/acsptsci.9b00085
    Journal articles | 2020
    Dr Jamie Fletcher
    Kamili A; Gifford AJ; Li N; Mayoh C; Chow S-O; Failes TW; Eden GL; Cadiz R; Xie J; Lukeis RE; Norris MD; Haber M; McCowage GB; Arndt GM; Trahair TN; Fletcher JI, 2020, 'Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy', British Journal of Cancer, http://dx.doi.org/10.1038/s41416-019-0682-4
    Journal articles | 2020
    Dr Jamie Fletcher
    Kamili A; Atkinson C; Trahair TN; Fletcher JI, 2020, 'Mouse models of high-risk neuroblastoma', Cancer and Metastasis Reviews, http://dx.doi.org/10.1007/s10555-020-09855-0
    Journal articles | 2019
    Dr Jamie Fletcher
    Gamble LD; Purgato S; Murray J; Xiao L; Yu DMT; Hanssen KM; Giorgi FM; Carter DR; Gifford AJ; Valli E; Milazzo G; Kamili A; Mayoh C; Liu B; Eden G; Sarraf S; Allan S; Giacomo SD; Flemming CL; Russell AJ; Cheung BB; Oberthuer A; London WB; Fischer M; Trahair TN; Fletcher JI; Marshall GM; Ziegler DS; Hogarty MD; Burns MR; Perini G; Norris MD; Haber M, 2019, 'Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma', Science Translational Medicine, vol. 11, http://dx.doi.org/10.1126/scitranslmed.aau1099
    Journal articles | 2019
    Dr Jamie Fletcher
    Boutros R; Catchpoole D; Collins K; Cross S; Downie P; Drinkwater C; Fletcher J; Gottardo N; Hunter S; Kirby M; Ludlow L; MacNish M; Maybury M; Moore A; Morrin H; Purdy S; Revesz T; Saffery R; Strong R; Trahair T; Wood A; Byrne J, 2019, 'The Australian and New Zealand Children's Haematology/Oncology Group Biobanking Network', Biopreservation and Biobanking, vol. 17, pp. 95 - 97, http://dx.doi.org/10.1089/bio.2019.0013
    Journal articles | 2019
    Dr Jamie Fletcher
    Koach J; Holien JK; Massudi H; Carter DR; Ciampa OC; Herath M; Lim T; Seneviratne JA; Milazzo G; Murray JE; McCarroll JA; Liu B; Mayoh C; Keenan B; Stevenson BW; Gorman MA; Bell JL; Doughty L; Hüttelmaier S; Oberthuer A; Fischer M; Gifford AJ; Liu T; Zhang X; Zhu S; Gustafson WC; Haber M; Norris MD; Fletcher JI; Perini G; Parker MW; Cheung BB; Marshall GM, 2019, 'Drugging MYCN oncogenic signaling through the MYCN-PA2G4 binding interface', Cancer Research, vol. 79, pp. 5652 - 5667, http://dx.doi.org/10.1158/0008-5472.CAN-19-1112
    Journal articles | 2019
    Dr Jamie Fletcher
    Gana CC; Hanssen KM; Yu DMT; Flemming CL; Wheatley MS; Conseil G; Cole SPC; Norris MD; Haber M; Fletcher JI, 2019, 'MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells', Biochemical Pharmacology, vol. 168, pp. 237 - 248, http://dx.doi.org/10.1016/j.bcp.2019.07.009
    Journal articles | 2018
    Dr Jamie Fletcher
    Fletcher JI; Ziegler DS; Trahair TN; Marshall GM; Haber M; Norris MD, 2018, 'Too many targets, not enough patients: Rethinking neuroblastoma clinical trials', Nature Reviews Cancer, vol. 18, pp. 389 - 400, http://dx.doi.org/10.1038/s41568-018-0003-x
    Journal articles | 2017
    Dr Jamie Fletcher
    Jung MS; Russell AJ; Liu B; George J; Liu PY; Liu T; DeFazio A; Bowtell DDL; Oberthuer A; London WB; Fletcher JI; Haber M; Norris MD; Henderson MJ, 2017, 'A Myc activity signature predicts poor clinical outcomes in Myc-associated cancers', Cancer Research, vol. 77, pp. 971 - 981, http://dx.doi.org/10.1158/0008-5472.CAN-15-2906
    Journal articles | 2017
    Dr Jamie Fletcher
    Murray J; Valli E; Yu DMT; Truong AM; Gifford AJ; Eden GL; Gamble LD; Hanssen KM; Flemming CL; Tan A; Tivnan A; Allan S; Saletta F; Cheung L; Ruhle M; Schuetz JD; Henderson MJ; Byrne JA; Norris MD; Haber M; Fletcher JI, 2017, 'Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo', European Journal of Cancer, vol. 83, pp. 132 - 141, http://dx.doi.org/10.1016/j.ejca.2017.06.024
    Journal articles | 2016
    Dr Jamie Fletcher
    Tee AE; Liu B; Song R; Li J; Pasquier E; Cheung BB; Jiang C; Marshall GM; Haber M; Norris MD; Fletcher JI; Dinger ME; Liu T, 2016, 'The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression', Oncotarget, vol. 7, pp. 8663 - 8675, http://dx.doi.org/10.18632/oncotarget.6675
    Journal articles | 2016
    Dr Jamie Fletcher
    Fletcher JI; Williams RT; Henderson MJ; Norris MD; Haber M, 2016, 'ABC transporters as mediators of drug resistance and contributors to cancer cell biology', Drug Resistance Updates, vol. 26, pp. 1 - 9, http://dx.doi.org/10.1016/j.drup.2016.03.001
    Journal articles | 2016
    Dr Jamie Fletcher
    Carter DR; Sutton SK; Pajic M; Murray J; Sekyere EO; Fletcher J; Beckers A; De Preter K; Speleman F; George RE; Haber M; Norris MD; Cheung BB; Marshall GM, 2016, 'Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis', Molecular Oncology, vol. 10, pp. 866 - 878, http://dx.doi.org/10.1016/j.molonc.2016.02.004
    Journal articles | 2016
    Dr Jamie Fletcher
    Koach J; Murray JE; McCarroll J; Milazzo G; Perini G; Haber M; Norris MD; Fletcher JI; Cheung BB; Marshall GM, 2016, 'Proffered Paper: Targeting PA2G4, a novel MYCN co-factor, for the treatment of neuroblastoma', European Journal of Cancer, vol. 61, pp. S7 - S7, http://dx.doi.org/10.1016/s0959-8049(16)61016-x
    Journal articles | 2016
    Dr Jamie Fletcher
    O'Brien R; Tran SL; Maritz MF; Liu B; Kong CF; Purgato S; Yang C; Murray J; Russell AJ; Flemming CL; von Jonquieres G; Pickett HA; London WB; Haber M; Gunaratne PH; Norris MD; Perini G; Fletcher JI; MacKenzie KL, 2016, 'MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin', Cancer Research, vol. 76, pp. 3604 - 3617, http://dx.doi.org/10.1158/0008-5472.CAN-15-0879
    Journal articles | 2015
    Dr Jamie Fletcher
    Cheung L; Yu DMT; Neiron Z; Failes TW; Arndt GM; Fletcher JI, 2015, 'Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen', Biochemical Pharmacology, vol. 93, pp. 380 - 388, http://dx.doi.org/10.1016/j.bcp.2014.11.006
    Journal articles | 2015
    Dr Jamie Fletcher
    Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD; Marshall GM; Haber M; Fletcher JI; Ashton LJ, 2015, 'MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma', Oncotarget, vol. 6, pp. 15510 - 15523, http://dx.doi.org/10.18632/oncotarget.3732
    Journal articles | 2014
    Dr Jamie Fletcher
    Byrne FL; Yang L; Phillips PA; Hansford LM; Fletcher JI; Ormandy CJ; McCarroll JA; Kavallaris M, 2014, 'RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model', Oncogene, vol. 33, pp. 882 - 890, http://dx.doi.org/10.1038/onc.2013.11
    Journal articles | 2014
    Dr Jamie Fletcher
    Cheung L; Flemming CL; Watt F; Masada N; Yu DMT; Huynh T; Conseil G; Tivnan A; Polinsky A; Gudkov AV; Munoz MA; Vishvanath A; Cooper DMF; Henderson MJ; Cole SPC; Fletcher JI; Haber M; Norris MD, 2014, 'High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4)', Biochemical Pharmacology, vol. 91, pp. 97 - 108, http://dx.doi.org/10.1016/j.bcp.2014.05.023
    Journal articles | 2012
    Dr Jamie Fletcher
    Fletcher JI; Gherardi S; Murray J; Burkhart C; Russell A; Valli E; Smith J; Oberthuer A; Ashton LJ; London WB; Marshall GM; Norris MD; Perini G; Haber M, 2012, 'N-Myc Regulates Expression of the Detoxifying Enzyme Glutathione Transferase GSTP1, a Marker of Poor Outcome in Neuroblastoma', Cancer Research, vol. 72, pp. 845 - 853, http://dx.doi.org/10.1158/0008-5472.CAN-11-1885
    Journal articles | 2011
    Dr Jamie Fletcher
    Henderson M; Haber M; Porro A; Munoz M; Xue C; Murray JE; Flemming C; Smith J; Fletcher JI; Gherardi S; Kwek C; Russell AJ; Valli E; London WB; Buxton AB; Ashton LJ; Sartorelli AC; Cohn SL; Schwab M; Marshall GM; Perini G; Norris MD, 2011, 'ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux', Journal of the National Cancer Institute, vol. 103, pp. 1236 - 1251, http://dx.doi.org/10.1093/jcni/djr256
    Journal articles | 2011
    Dr Jamie Fletcher
    Kvansakul M; Wei AH; Fletcher JI; Willis SN; Chen L; Roberts AW; Huang DCS; Colman PM, 2011, 'Structural basis for the inhibition of apoptosis by Epstein–Barr virus BHRF1', Acta Crystallographica Section A Foundations of Crystallography, vol. 67, pp. C76 - C76, http://dx.doi.org/10.1107/s010876731109814x
    Journal articles | 2011
    Dr Jamie Fletcher
    Neiron Z; Jankowski K; Murray J; Champion S; Norris MD; Haber M; Fletcher JI, 2011, 'Development of organ-selective neuroblastoma cell lines to identify genes mediating bone marrow and liver colonization', CANCER RESEARCH, vol. 71, http://dx.doi.org/10.1158/1538-7445.AM2011-5237
    Journal articles | 2010
    Dr Jamie Fletcher
    Kvansakul M; Wei AH; Fletcher JI; Willis SN; Chen L; Roberts AW; Huang DCS; Colman PM, 2010, 'Structural basis for apoptosis inhibition by Epstein-Barr virus bhrf1', PLoS Pathogens, vol. 6, http://dx.doi.org/10.1371/journal.ppat.1001236
    Journal articles | 2010
    Dr Jamie Fletcher
    Fletcher JI; Haber M; Henderson M; Norris MD, 2010, 'ABC transporters in cancer: more than just drug efflux pumps', Nature Reviews Cancer, vol. 10, pp. 147 - 156, http://dx.doi.org/10.1038/nrc2789
    Journal articles | 2009
    Dr Jamie Fletcher
    Branson KM; Mertens HDT; Swarbrick JD; Fletcher JI; Kedzierski L; Gayler KR; Gooley PR; Smith BJ, 2009, 'Discovery of Inhibitors of Lupin Diadenosine 5 ',5 '''-P-1,P-4-Tetraphosphate Hydrolase by Virtual Screening', BIOCHEMISTRY, vol. 48, pp. 7614 - 7620, http://dx.doi.org/10.1021/bi900813x
    Journal articles | 2008
    Dr Jamie Fletcher
    Fletcher JI; Meusburger S; Hawkins CJ; Riglar DT; Lee EF; Fairlie WD; Huang DCS; Adams JM, 2008, 'Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax', Proceedings of the National Academy of Sciences of the United States of America, vol. 105, pp. 18081 - 18087, http://dx.doi.org/10.1073/pnas.0808691105
    Journal articles | 2008
    Dr Jamie Fletcher
    Fletcher JI; Huang DCS, 2008, 'Controlling the cell death mediators Bax and Bak - Puzzles and conundrums', CELL CYCLE, vol. 7, pp. 39 - 44, http://dx.doi.org/10.4161/cc.7.1.5178
    Journal articles | 2007
    Dr Jamie Fletcher
    Mason KD; Carpinelli MR; Fletcher JI; Collinge JE; Hilton AA; Ellis S; Kelly PN; Ekert PG; Metcalf D; Roberts AW; Huang DCS; Kile BT, 2007, 'Programmed Anuclear Cell Death Delimits Platelet Life Span', Cell, vol. 128, pp. 1173 - 1186, http://dx.doi.org/10.1016/j.cell.2007.01.037
    Journal articles | 2007
    Dr Jamie Fletcher
    Willis SN; Fletcher JI; Kaufmann T; van Delft MF; Chen L; Czabotar PE; Ierino H; Lee EF; Fairlie WD; Bouillet P; Strasser A; Kluck RM; Adams JM; Huang DCS, 2007, 'Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak', SCIENCE, vol. 315, pp. 856 - 859, http://dx.doi.org/10.1126/science.1133289
    Journal articles | 2006
    Dr Jamie Fletcher
    Mason KD; Carpinelli MR; Collinge JE; Hilton AA; Fletcher JI; Roberts AW; Metcalf D; Huang DCS; Kile BT, 2006, 'The Bcl-2 Protein Family Is Essential for Platelet Survival In Vivo.', Blood, vol. 108, pp. 697 - 697, http://dx.doi.org/10.1182/blood.v108.11.697.697
    Journal articles | 2006
    Dr Jamie Fletcher
    Fletcher JI; Huang DCS, 2006, 'BH3-only proteins: orchestrating cell death', CELL DEATH AND DIFFERENTIATION, vol. 13, pp. 1268 - 1271, http://dx.doi.org/10.1038/sj.cdd.4401995
    Journal articles | 2005
    Dr Jamie Fletcher
    Willis SN; Chen L; Dewson G; Wei A; Naik E; Fletcher JI; Adams JM; Huang DCS, 2005, 'Proapoptotic Bak is sequestered by Mcl-1 and Bcl-x(L), but not Bcl-2, until displaced by BH3-only proteins', GENES & DEVELOPMENT, vol. 19, pp. 1294 - 1305, http://dx.doi.org/10.1101/gad.1304105
    Journal articles | 2005
    Dr Jamie Fletcher
    Chen L; Willis SN; Wei A; Smith BJ; Fletcher JI; Hinds MG; Colman PM; Day CL; Adams JM; Huang DCS, 2005, 'Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function', MOLECULAR CELL, vol. 17, pp. 393 - 403, http://dx.doi.org/10.1016/j.molcel.2004.12.030
    Journal articles | 2005
    Dr Jamie Fletcher
    Voskoboinik I; Thia MC; Fletcher J; Ciccone A; Browne K; Smyth MJ; Trapani JA, 2005, 'Calcium-dependent plasma membrane binding and cell lysis by perforin are mediated through its C2 domain', JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, pp. 8426 - 8434, http://dx.doi.org/10.1074/jbc.M413303200
    Journal articles | 2005
    Dr Jamie Fletcher
    Adams JM; Huang DCS; Strasser A; Willis S; Chen L; Wei A; Van Delft M; Fletcher JI; Puthalakath H; Kuroda J; Michalak EM; Kelly PN; Bouillet P; Villunger A; O'Reilly L; Bath ML; Smith DP; Egle A; Harris AW; Hinds M; Colman P; Cory S, 2005, 'Subversion of the Bcl-2 life/death switch in cancer development and therapy', Molecular Approaches to Controlling Cancer, vol. 70, pp. 469 - 477, http://dx.doi.org/10.1101/sqb.2005.70.009
    Journal articles | 2005
    Dr Jamie Fletcher
    Swarbrick JD; Buyya S; Gunawardana D; Fletcher JI; Branson K; Smith B; Pepe S; McLennan A; Gayler KR; Gooley PR, 2005, 'Letter to the Editor: H-1, C-13, and N-15 resonance assignments of the 17 kDa Ap4A hydrolase from Homo sapiens in the presence and absence of ATP', JOURNAL OF BIOMOLECULAR NMR, vol. 31, pp. 181 - 182, http://dx.doi.org/10.1007/s10858-004-7440-4
    Journal articles | 2004
    Dr Jamie Fletcher
    de Planque MRR; Rijkers DTS; Fletcher JI; Liskamp RMJ; Separovic F, 2004, 'The alpha-M1 segment of the nicotinic acetylcholine receptor exhibits conformational flexibility in a membrane environment', BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, vol. 1665, pp. 40 - 47, http://dx.doi.org/10.1016/j.bbamem.2004.06.021
    Journal articles | 2002
    Dr Jamie Fletcher
    Fletcher JI; Swarbrick JD; Maksel D; Gayler KR; Gooley PR, 2002, 'The structure of Ap(4)A hydrolase complexed with ATP-MgFx reveals the basis of substrate binding', STRUCTURE, vol. 10, pp. 205 - 213, http://dx.doi.org/10.1016/S0969-2126(02)00696-2
    Journal articles | 2001
    Dr Jamie Fletcher
    Tedford HW; Fletcher JI; King GF, 2001, 'Functional Significance of the β-Hairpin in the Insecticidal Neurotoxin ω-Atracotoxin-Hv1a', Journal of Biological Chemistry, vol. 276, pp. 26568 - 26576, http://dx.doi.org/10.1074/jbc.M102199200
    Journal articles | 1999
    Dr Jamie Fletcher
    Wang XH; Smith R; Fletcher JI; Wilson H; Wood CJ; Howden MEH; King GF, 1999, 'Structure-function studies of ω-atracotoxin, a potent antagonist of insect voltage-gated calcium channels', European Journal of Biochemistry, vol. 264, pp. 488 - 494, http://dx.doi.org/10.1046/j.1432-1327.1999.00646.x
    Journal articles | 1999
    Dr Jamie Fletcher
    Fletcher JI; Dingley AJ; Smith R; Connor M; Christie MJ; King GF, 1999, 'High-resolution solution structure of gurmarin, a sweet-taste- suppressing plant polypeptide', European Journal of Biochemistry, vol. 264, pp. 525 - 533, http://dx.doi.org/10.1046/j.1432-1327.1999.00659.x
    Journal articles | 1999
    Dr Jamie Fletcher
    Torres AM; Wang X; Fletcher JI; Alewood D; Alewood PF; Smith R; Simpson RJ; Nicholson GM; Sutherland SK; Gallagher CH; King GF; Kuchel PW, 1999, 'Solution structure of a defensin-like peptide from platypus venom', Biochemical Journal, vol. 341, pp. 785 - 794, http://dx.doi.org/10.1042/0264-6021:3410785
    Journal articles | 1999
    Dr Jamie Fletcher
    Fletcher JI; Wang X; Connor M; Christie MJ; King GF; Nicholson GM, 1999, 'Spider toxins: A new group of potassium channel modulators', Perspectives in Drug Discovery and Design, vol. 15-16, pp. 61 - 69, http://dx.doi.org/10.1023/A:1017039418046
    Journal articles | 1997
    Dr Jamie Fletcher
    Fletcher JI; Chapman BE; Mackay JP; Howden MEH; King GF, 1997, 'The structure of versutoxin (δ-atracotoxin-Hv1) provides insights into the binding of site 3 neurotoxins to the voltage-gated sodium channel', Structure, vol. 5, pp. 1525 - 1535, http://dx.doi.org/10.1016/S0969-2126(97)00301-8
    Journal articles | 1997
    Dr Jamie Fletcher
    Fletcher JI; Smith R; O Donoghue SI; Nilges M; Connor M; Howden MEH; Christie MJ; King GF, 1997, 'The structure of a novel insecticidal neurotoxin, atracotoxin-HVI, from the venom of an Australian funnel web spider', Nature Structural Biology, vol. 4, pp. 559 - 566, http://dx.doi.org/10.1038/nsb0797-559
  • Conference Abstracts | 2019
    Dr Jamie Fletcher
    Chen J; Nelson C; Liu P; Tee AE; Atmadibrata B; MacKenzie K; Fletcher J; Trahair T; Polly P; Reddel R; Pickett H; Liu T, 2019, 'Efficacious targeting of TERT oncogene rearrangement with BET bromodomain inhibitor and proteasome inhibitor combination therapy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Atlanta, GA, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta, GA, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-5209
    Conference Abstracts | 2019
    Dr Jamie Fletcher
    Chen J; Nelson C; Liu P; Tee AE; Atmadibrata B; MacKenzie K; Fletcher J; Trahair T; Polly P; Reddel R; Pickett H; Liu T, 2019, 'Abstract 5209: Efficacious targeting of TERT oncogene rearrangement with BET bromodomain inhibitor and proteasome inhibitor combination therapy', in Molecular and Cellular Biology / Genetics, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-5209
    Conference Abstracts | 2019
    Dr Jamie Fletcher
    Kamili A; Gifford AJ; Li N; Mayoh C; Eden GL; Xie J; Lukeis RE; Norris MD; Haber M; McCowage G; Trahair TN; Fletcher JI, 2019, 'Abstract 2884: Establishment of patient-derived xenograft models for high-risk neuroblastoma', in Tumor Biology, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-2884
    Conference Abstracts | 2019
    Dr Jamie Fletcher
    Fordham AM; Blackburn J; Heyer EE; Xie J; Mould EV; Gifford AJ; Morgan LT; Wadham C; Fadia M; Fletcher JI; MacKenzie KL; Trahair TN, 2019, 'Abstract 4824: Targeting CD30 as a novel treatment strategy inRANBP2-ALK-rearranged inflammatory myofibroblastic tumor', in Experimental and Molecular Therapeutics, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-4824
    Conference Abstracts | 2019
    Dr Jamie Fletcher
    Atkinson C; Tactacan CM; Kamili A; Saletta F; Gana C; Eden GL; Mayoh C; Lock RB; Norris MD; Haber M; Gifford AJ; Trahair TN; Fletcher JI, 2019, 'Abstract 4741: Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', in Experimental and Molecular Therapeutics, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.am2019-4741
    Conference Papers | 2019
    Dr Jamie Fletcher
    Hanssen KM; Gana CC; Wheatley MS; Yu DM; Flemming CL; Young R; Wright GM; Conseil G; Kennedy CJ; deFazio A; Solomon B; Cole SP; Norris MD; Haber M; Fletcher JI, 2019, 'Abstract 3809: Modulation of MRP1 activity reverses chemotherapy resistance in adult cancer cells', in Experimental and Molecular Therapeutics, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-3809
    Conference Papers | 2019
    Dr Jamie Fletcher
    Hanssen KM; Gana CC; Wheatley MS; Yu DM; Flemming CL; Young R; Wright GM; Conseil G; Kennedy CJ; deFazio A; Solomon B; Cole SP; Norris MD; Haber M; Fletcher JI, 2019, 'Abstract 3809: Modulation of MRP1 activity reverses chemotherapy resistance in adult cancer cells', in Experimental and Molecular Therapeutics, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.am2019-3809
    Conference Abstracts | 2019
    Dr Jamie Fletcher
    Atkinson C; Tactacan CM; Kamili A; Saletta F; Gana C; Eden GL; Mayoh C; Lock RB; Norris MD; Haber M; Gifford AJ; Trahair TN; Fletcher JI, 2019, 'Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Atlanta, GA, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta, GA, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.SABCS18-4741
    Conference Abstracts | 2019
    Dr Jamie Fletcher
    Kamili A; Gifford AJ; Li N; Mayoh C; Eden GL; Xie J; Lukeis RE; Norris MD; Haber M; McCowage G; Trahair TN; Fletcher JI, 2019, 'Establishment of patient-derived xenograft models for high-risk neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Atlanta, GA, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta, GA, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-2884
    Conference Abstracts | 2019
    Dr Jamie Fletcher
    Fordham AM; Blackburn J; Heyer EE; Xie J; Mould EV; Gifford AJ; Morgan LT; Wadham C; Fadia M; Fletcher JI; MacKenzie KL; Trahair TN, 2019, 'Targeting CD30 as a novel treatment strategy in RANBP2-ALK-rearranged inflammatory myofibroblastic tumor', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Atlanta, GA, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta, GA, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-4824
    Conference Abstracts | 2017
    Dr Jamie Fletcher
    Lau L; Byrne J; Ekert PG; Failes T; Fellowes A; Fletcher J; Gifford A; Haber M; Kumar A; Lock R; Marshall G; McCowage GB; Mould E; Norris M; Trahair T; Tsoli M; Tyrrell V; Wadham C; Xie J; Ziegler DS, 2017, 'Pilot study of a comprehensive precision medicine platform for children with high-risk cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Chicago, IL, Vol. 35, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 02 June 2017 - 06 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.10539
    Conference Papers | 2017
    Dr Jamie Fletcher
    Gana CC; Hanssen K; Yu DM; Flemming C; Norris M; Haber M; Fletcher J, 2017, 'A modulator of multidrug resistance protein 1 selectively depletes glutathione and synergizes with L-buthionine sulfoximine to sensitize MRP1-expressing cancer cells to chemotherapy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 01 April 2017 - 05 April 2017, http://dx.doi.org/10.1158/1538-7445.AM2017-4056
    Conference Papers | 2017
    Dr Jamie Fletcher
    Gao J; Somers K; Hannan KM; Fletcher JI; Liu B; Hannan RD; Pearson RB; Haber M; Norris MD; Henderson MJ, 2017, 'Abstract 1956: ABCE1 regulates the translational profile of neuroblastoma to drive tumor progression', in Tumor Biology, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC, http://dx.doi.org/10.1158/1538-7445.am2017-1956
    Conference Papers | 2015
    Dr Jamie Fletcher
    Koach J; Liu B; Bell JL; Huettelmaier S; Liu T; Carter DR; Haber M; Norris MD; Fletcher J; Cheung BB; Marshall GM, 2015, 'PA2G4 predicts poor prognosis in neuroblastoma patients and promotes neuroblastoma progression by enhancing MYCN protein stability', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Philadelphia, PA, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Philadelphia, PA, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-962
    Conference Papers | 2015
    Dr Jamie Fletcher
    O'Brien R; Maritz MF; Kong CF; Purgato S; Liu B; Yang C; Russell A; Murray J; Flemming C; Haber M; Perini G; Norris MD; Fletcher JI; Mackenzie KL, 2015, 'Abstract 488: High DKC1 expression supports neuroblastoma tumor cell proliferation and is strongly associated with poor patient outcomes', in Tumor Biology, American Association for Cancer Research, presented at Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA, http://dx.doi.org/10.1158/1538-7445.am2015-488
    Conference Abstracts | 2012
    Dr Jamie Fletcher
    Byrne FL; Phillips PA; Hansford LM; Fletcher JI; Ormandy CJ; McCarroll JA; Kavallaris M, 2012, 'Stathmin suppression influences ROCK signaling and reduces cell invasion and metastasis in neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 72, http://dx.doi.org/10.1158/1538-7445.AM2012-1444
    Conference Papers | 2012
    Dr Jamie Fletcher
    Huynh T; Tivnan A; Munoz M; Cheung L; Vishvanath A; Flemming C; Watt F; Burkhart C; Gudkov A; Fletcher J; Henderson M; Norris M; Haber M, 2012, 'Abstract 1834: Targeting ABC transporters in cancer through small molecule inhibitors', in Experimental and Molecular Therapeutics, American Association for Cancer Research, presented at Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL, http://dx.doi.org/10.1158/1538-7445.am2012-1834
    Conference Papers | 2012
    Dr Jamie Fletcher
    Norris MD; Fletcher JI; Gherardi S; Murray J; Burkhart C; Russell A; Valli E; Oberthuer A; Ashton LJ; London WB; Marshall GM; Perini G; Haber M, 2012, 'GSTP1 expression is regulated by MycN and is a marker of poor outcome in childhood neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1538-7445.AM2012-789
    Conference Papers | 2011
    Dr Jamie Fletcher
    Norris MD; Henderson MJ; Porro A; Munoz M; Iraci N; Xue C; Murray J; Flemming C; Fletcher J; Gherardi S; Kwek A; Russell A; London WB; Buxton AB; Ashton L; Sartorelli AC; Cohn SL; Schwab M; Marshall GM; Perini G; Haber M, 2011, 'ABCC/MRP multidrug transporters contribute to neuroblastoma biology, pathogenesis and clinical outcome, independently of any role in cytotoxic drug efflux', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1538-7445.AM2011-954

Awards

UNSW ARC Postgraduate Council Supervisor Award 2018

UNSW Faculty of Medicine Dean’s Rising Star Award 2011

Children's Cancer Institute Award 2011

Cancer Institute NSW Career Development & Support Fellowship 2010

Balnaves Foundation Young Researcher’s Fund Award 2008

NHMRC Peter Doherty Fellowship 2000

Grants

Current research support

NHMRC Ideas Grant; 2020–2021; Improving induction therapy for high-risk neuroblastoma through bypass or inhibition of P-glycoprotein (APP1182974)

Children’s Cancer Foundation; 2019–2022; Leveraging the SIOPEN High risk 2.0 clinical trial for high-risk neuroblastoma to understand relapse, improve residual disease detection and develop pre-clinical testing models for high-risk neuroblastoma

NHMRC Project Grant; 2018–2020; Precision medicine for high-risk neuroblastoma (APP1146817)

NHMRC Development Grant; 2018–2020; Multidrug Resistance Protein 1 inhibitors to sensitise cancers to chemotherapy (APP1136278)

Neuroblastoma Australia; 2018–2020; Characterization of high-risk neuroblastoma models to support translational research

Neuroblastoma Australia; 2018–2019; Optimization of high-risk neuroblastoma model development

Media